Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | CA4 | P22748 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10978146 | 0.86 | CA2 (0.54) | CA2CA1CA4CA12CA14 | |
| SCHEMBL4011584 | 0.79 | RAB9A (0.56) | — | |
| SCHEMBL10347747 | 0.79 | CA2 (0.58) | CA2CA1CA4CA12CA14 | |
| SCHEMBL10348598 | 0.78 | CA2 (0.57) | CA2CA1CA4CA12CA14 | |
| SCHEMBL10980308 | 0.76 | CA2 (0.59) | CA2CA1CA4CA12CA14 | |
| SCHEMBL7933450 | 0.75 | CA2 (0.81) | CA2CA1 | |
| SCHEMBL10982158 | 0.75 | CA2 (0.59) | CA2CA1CA4CA12CA14 | |
| SCHEMBL10348109 | 0.74 | CA2 (0.52) | CA2CA1CA4CA12CA14 | |
| SCHEMBL564235 | 0.74 | CA2 (1.00) | CA2CA1CA4CA12CA14 | |
| SCHEMBL14317794 | 0.74 | CA2 (0.67) | CA2CA1CA4CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659312-B2 | Inhibitors of Aquaporin 4, methods and uses thereof | NIIGATA UNIVERSITY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659312-B2 | Inhibitors of Aquaporin 4, methods and uses thereof | NIIGATA UNIVERSITY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | NIIGATA UNIVERSITY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | NIIGATA UNIVERSITY (JP) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | AQP4, AQP1, AQP3 | CA2 187/4885CA1 563/4885CA4 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.